phrykt

Processa Pharmaceuticals, Inc. (PCSA): who owns it and who trades it

As of Nov 16, 2026, PCSA insiders reported 42 purchases worth $209K in the last 12 months. The largest buyer was Russell Skibsted (CFO), with $41.7K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Processa Pharmaceuticals

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, PCSA insiders reported $209K of open-market purchases and $0 of sales.

Purchases, 12 months
$209K
42 trades, 9 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Jul 1, 2026
Filed Jul 1, 2026

Purchases and sales by month

$65.5K$65.5KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 1, 2026George K NgCEOPurchase3,057$1.93$5.9KForm 4
Jun 30, 2026Wendy GuyChief Administrative OffPurchase2,436$1.93$4.7KForm 4
Jun 30, 2026Patrick LinChief Business - StrategPurchase2,106$1.93$4.1KForm 4
Jun 30, 2026Russell SkibstedCFOPurchase3,277$1.93$6.3KForm 4
Jun 30, 2026David YoungDirectorPurchase2,531$1.93$4.9KForm 4
Jun 15, 2026David YoungDirectorPurchase2,067$2.22$4.6KForm 4
Jun 15, 2026Russell SkibstedCFOPurchase2,654$2.22$5.9KForm 4
Jun 15, 2026George K NgCEOPurchase2,465$2.22$5.5KForm 4
Jun 15, 2026Patrick LinChief Business - StrategPurchase1,831$2.22$4.1KForm 4
Jun 15, 2026Wendy GuyChief Administrative OffPurchase2,118$2.22$4.7KForm 4
May 29, 2026David YoungDirectorPurchase1,786$2.57$4.6KForm 4
May 29, 2026Russell SkibstedCFOPurchase2,292$2.57$5.9KForm 4
May 29, 2026George K NgCEOPurchase2,129$2.57$5.5KForm 4
May 29, 2026Patrick LinChief Business - StrategPurchase1,582$2.57$4.1KForm 4
May 29, 2026Wendy GuyChief Administrative OffPurchase1,829$2.57$4.7KForm 4
May 15, 2026George K NgCEOPurchase1,843$2.97$5.5KForm 4
May 15, 2026David YoungDirectorPurchase1,545$2.97$4.6KForm 4
May 15, 2026Patrick LinChief Business - StrategPurchase1,369$2.97$4.1KForm 4
May 15, 2026Wendy GuyChief Administrative OffPurchase1,583$2.97$4.7KForm 4
May 15, 2026Russell SkibstedCFOPurchase1,984$2.97$5.9KForm 4
Apr 30, 2026Sian BigoraChief Development OfficePurchase1,971$2.71$5.3KForm 4
Apr 30, 2026David YoungDirectorPurchase1,706$2.69$4.6KForm 4
Apr 30, 2026Russell SkibstedCFOPurchase2,190$2.69$5.9KForm 4
Apr 30, 2026George K NgCEOPurchase2,034$2.69$5.5KForm 4
Apr 30, 2026Patrick LinChief Business - StrategPurchase1,511$2.69$4.1KForm 4
Apr 30, 2026Wendy GuyChief Administrative OffPurchase1,748$2.69$4.7KForm 4
Apr 30, 2026Sian BigoraChief Development OfficePurchase1,986$2.69$5.3KForm 4
Apr 15, 2026George K NgCEOPurchase1,843$2.97$5.5KForm 4
Apr 15, 2026David YoungDirectorPurchase1,545$2.97$4.6KForm 4
Apr 15, 2026Patrick LinChief Business - StrategPurchase1,369$2.97$4.1KForm 4
Apr 15, 2026Wendy GuyChief Administrative OffPurchase1,583$2.97$4.7KForm 4
Apr 15, 2026Sian BigoraChief Development OfficePurchase1,799$2.97$5.3KForm 4
Apr 15, 2026Russell SkibstedCFOPurchase1,984$2.97$5.9KForm 4
Mar 31, 2026George K NgCEOPurchase2,136$2.54$5.4KForm 4
Mar 31, 2026James R NealDirectorPurchase789$2.54$2KForm 4
Mar 31, 2026David YoungDirectorPurchase1,810$2.54$4.6KForm 4
Mar 31, 2026Russell SkibstedCFOPurchase2,324$2.54$5.9KForm 4
Mar 31, 2026Geraldine PannuDirectorPurchase2,072$2.54$5.3KForm 4
Mar 31, 2026Patrick LinChief Business - StrategPurchase1,603$2.54$4.1KForm 4
Mar 31, 2026Wendy GuyChief Administrative OffPurchase1,854$2.54$4.7KForm 4
Mar 31, 2026Sian BigoraChief Development OfficePurchase2,107$2.54$5.4KForm 4
Mar 31, 2026Khoso BaluchDirectorPurchase2,269$2.54$5.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Russell SkibstedChief Financial Officer$41.7K–Jun 30, 2026
George K NgChief Executive Officer, Director$38.7K–Jul 1, 2026
Wendy GuyChief Administrative Officer$32.9K–Jun 30, 2026
David YoungPres. Research & Development, Director$32.4K–Jun 30, 2026
Patrick LinChief Business - Strategy Off$28.5K–Jun 30, 2026
Sian BigoraChief Development Officer$21.4K–Apr 30, 2026
Khoso BaluchDirector$5.8K–Mar 31, 2026
Geraldine PannuDirector$5.3K–Mar 31, 2026
James R NealDirector$2K–Mar 31, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PCSA short interest

Low short interest. 0.9% of PCSA shares are sold short: about 1 share in 107. Over the last 12 reports the number of shares short went down 78%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 26,138 PCSA shares were sold short, 0.9% of the shares outstanding, down 43.8% from the report before. At the average daily volume of 27,704 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.94%May 15Oct 309.31%

Days to cover

1.0May 15Oct 302.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202626,1380.94%-44%27,7041.0
Oct 15, 202646,4881.66%+1023%329,0901.0
Sep 30, 20264,1400.15%-72%23,0951.0
Sep 15, 202614,9950.54%-58%29,0281.0
Aug 31, 202635,9491.29%-47%35,7051.0
Aug 14, 202667,3192.41%-69%78,5711.0
Jul 31, 2026215,8518.11%+108%953,6711.0
Jul 15, 2026103,5543.89%+20%74,1391.4
Jun 30, 202686,0543.24%-4%43,4642.0
Jun 15, 202689,9833.38%-1%78,7961.1
May 29, 202691,0633.42%-22%56,7741.6
May 15, 2026116,5944.38%-14%60,8421.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Processa Pharmaceuticals company events

Processa Pharmaceuticals filed 10 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026AnnouncementProcessa Pharmaceuticals, Inc. issued a letter to the Company’s stockholders. Filing
  2. Nov 4, 2026LeadershipThe Board approved the appointment of Gregory J. Flesher as Chief Operating Officer of the Company, effective November 4, 2026. Filing
  3. Oct 29, 2026AnnouncementJustin Yorke resigned as chair of the board of directors of Processa Pharmaceuticals, Inc., and on October 28, 2026, the Board appointed Dr. Sheila Gujrathi as the non-employee executive chair of the Board, effective immediately. Filing
  4. Oct 5, 2026AnnouncementAmended an earlier report. The information set forth in the “Business Section of the Company” reflecting the business of the Company following the acquisition of Vidya is attached hereto as Exhibit 99.3 and incorporated herein by reference. Filing
  5. Aug 4, 2026LeadershipProcessa Pharmaceuticals, Inc. held its 2026 Annual Meeting of Shareholders. Filing
  6. Jul 29, 2026LeadershipAppointment of Directors In accordance with the Merger Agreement, on July 28, 2026, effective immediately after the First Effective Time, Sheila Gujrathi was appointed to the Board as a director. Filing
  7. Apr 30, 2026LeadershipProcessa Pharmaceuticals, Inc. approved a transition in the employment status of Dr. Sian Bigora, the Company’s Chief Development and Regulatory Officer, as part of her planned transition toward retirement. Filing
  8. Feb 19, 2026AgreementEnded an important agreement. Filing
  9. Jan 7, 2026AnnouncementProcessa Pharmaceuticals, Inc. received written notification from the NASDAQ Stock Market Listing Qualifications Staff indicating that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the Nastadq Capital Market pursuant to NASDAQ… Filing
  10. Dec 15, 2025SharesChanged the rights of its shareholders. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Processa Pharmaceuticals financials

Famous investors that hold PCSA

2 of the 50 well-known investors we track reported holding PCSA in their latest 13F filing. The largest position is Israel Englander's, worth $2.4M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20261,875$2.4M0.0%New
Ken Griffin · Citadel AdvisorsQ3 202658,629$96.2K0.0%+175%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Processa Pharmaceuticals, Inc. (PCSA) stock

Are PCSA insiders buying or selling?

In the last 12 months, PCSA insiders reported 42 open-market purchases worth $209K and no sales. The latest trade was on Jul 1, 2026. See every trade.

What is the short interest in PCSA?

As of Oct 30, 2026, 26,138 PCSA shares were sold short, 0.9% of the shares outstanding, down 43.8% from the report before. At the average daily volume of 27,704 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold PCSA?

2 of the 50 well-known investors we track reported PCSA in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $2.4M. See all holders.

Executive pay

Processa Pharmaceuticals's chief executive was paid a total of $673K for the year ended Dec 31, 2025, up 29% from $521K the year before. In the last 12 months, Processa Pharmaceuticals's executives and directors bought $209K of stock on the open market and sold none.

Chief executive, total pay$673KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$565KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$531KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.